World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist

Read the original at Daily Mail ↗
Cite

Hynds, J. (2026, October 22). World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist. Daily Mail. https://www.dailymail.com/news/article-16231693/cancer-vaccine-trial-australia-georgina-long.html?ns_mchannel=rss&ns_campaign=1490&ito=1490

Dated from the outlet's own feed. Check the original for its byline.

Daily Mail · collected 2026-10-23 · by Joanna Hynds

Quick Summary

Professor Georgina Long led a world-first cancer vaccine trial that significantly reduced the risk of melanoma recurrence or death by 42% compared to patients treated with only pembrolizumab (Keytruda). The study, involving 1,137 participants across 157 global sites, tested an individualised mRNA vaccine called intismeran, developed by Moderna and MSD. This breakthrough could revolutionize cancer treatment, potentially improving survival rates for melanoma patients and possibly extending to other cancers as well.
Written locally by qwen2.5:14b on 2026-10-23, using this article's own text rather than the other coverage of the same event (that is the story summary below).

AI analysis runs on qwen2.5:14b, locally

Story summary

A large clinical trial combining Moderna's mRNA cancer vaccine with Merck's immunotherapy drug Keytruda has shown a 42% reduction in the risk of melanoma recurrence or death over two years. The Phase 3 study, involving more than 1,100 patients, also revealed that the combination therapy reduced the likelihood of cancer spreading by 38%. This breakthrough marks a significant step forward for personalized oncology and could pave the way for similar treatments targeting other types of cancers. However, both Moderna and Merck saw their stock prices drop on Thursday after the trial results were leaked online, with Moderna shares falling over 17% and Merck's down about 1.8%. The study was led by Australian scientist Professor Georgina Long from the University of Sydney, highlighting potential global applications for personalized cancer vaccines in treating melanoma and possibly other cancers.

Written for “mRNA Cancer Vaccine For Melanoma” on 2026-10-23, grounded in this article and the 3 other(s) covering the same event.

Story

📰 mRNA Cancer Vaccine For Melanoma
Health · 4 article(s) covering the same event. Compare every outlet's account →

Compared with similar articles

This article reads unscored and hedges 10% of its claims. Each row says how that neighbour differs.
The Independent
⚖️ leaning not scored 🔴 0% hedged 0 of 16 📰 publisher trust 59
“Both articles report on the same clinical trial results announced by Moderna and Merck regarding an mRNA cancer vaccine for melanoma that reduced death or recurrence risk by 42%. The trials are described as a world-first with Australian leadership.”
TIME
⚖️ leaning not scored 🔴 11% hedged 3 of 28 📰 publisher trust 59
“Both articles describe the identical clinical trial results presented on Oct. 22 about a personalized cancer vaccine for melanoma reducing recurrence or death risk by 42%, with the same study parameters and outcomes.”
Toronto Star
⚖️ leaning not scored 🔴 9% hedged 3 of 35 📰 publisher trust 64
“Both articles report on the release of results from a major study involving a new cancer vaccine by Moderna and Merck, which significantly reduced the risk of melanoma recurrence in patients.”
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
10
sentences that state something as happening or true
Uncertain
10%
1 of 10 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
64/100
Daily Mail's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
4
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-23 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Daily Mail · 7011 article(s) · 15 correction(s) detected
Running correction rate · 15 correction(s)

Who wrote this

Joanna Hynds
42 article(s) here · 1 carrying a prediction
🔮 The landmark findings could pave the way for personalised cancer vaccines to improve survival rates for patients with melanoma and potentially other cancers.
🔮 'I respect people's views and opinions out there and it wasn't as tastefully done as it could have been.
🔮 'I spoke about my own battle in parliament, not to get sympathy, as One Nation may suggest, but to let other women know they are not alone.
🔮 The Daily Mail has learned that 2GB breakfast host Ben Fordham has conducted a two hour interview with the SAS soldier that is set to air over two days this coming week on the Sydney radio station and YouTube.
🔮 A string of women have allegedly been sexually assaulted on popular walking trails across Sydney's Northern Beaches, as police hunt an e-bike rider who may be able to assist with inquiries.
🔮 A crime scene has been established and will be examined by specialist officers. Recreational Aviation Australia and the Australian Transport Safety Bureau (ATSB) have been notified of the crash.
🔮 A 42-year-old man was found dead after being shot outside his home Homicide detectives are investigating the circumstances surrounding his death, which police believe may have been a targeted attack Hamad was deported from Australia to Iraq in 2023. He was accused of being one of the key figures behind the Melbourne tobacco wars, which were allegedly linked to a series of firebombings across the city as rival groups battled for control of the billion-dollar illicit tobacco market.
🔮 Mr Annesley allegedly gave false details about his work contract, could not say how much he had invested and had no proof of his investment.
🔮 The woman allegedly told Ms Charles she had found the unit on Flatmates.com, but Ms Charles said the website confirmed that no listing could be found.
🔮 The court heard the six business-class flights to China were taken so Liu could visit her parents, who were affected by Covid.
Also by Joanna Hynds
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 42 articles by Joanna Hynds →

Topics

Keytruda Melanoma Institute Australia Sydney intismeran the University of Sydney

Subjects

Georgina Long PERSON · 2× Melanoma Institute Australia ORG · 2× Australian NORP · 1× Long PERSON · 1× MSD ORG · 1× Moderna ORG · 1× NSW GPE · 1× Sydney GPE · 1× Westmead Hospital ORG · 1× the University of Sydney ORG · 1×

Narrative

Professor Georgina Long (pictured) led the clinical trial of a world-first cancer vaccine that dramatically reduced the risk of melanoma recurrence or death The trial was conducted across 157 sites worldwide and involved 1,137 patients whose melanoma had been surgically removed but who remained at high risk of the cancer returning.
framing: assertive · carried by 1 article(s) · first seen 2026-10-23
🔮 The landmark findings could pave the way for personalised cancer vaccines to improve survival rates for patients with melanoma and potentially other cancers.

Claims (10 extracted, 1 hedged)

A Sydney scientist is leading a world-first cancer vaccine trial that has dramatically reduced the risk of melanoma returning or patients dying from the disease. asserted
melanoma → lead → disease
The study found the vaccine cut the risk of cancer recurrence or death by 42 per cent compared with patients who received only an immunotherapy drug, pembrolizumab, which is sold under the brand name Keytruda. asserted
which → find → name
The landmark findings could pave the way for personalised cancer vaccines to improve survival rates for patients with melanoma and potentially other cancers. uncertain
vaccines → pave → melanoma
'These results show that patients with earlier-stage melanoma can be treated after surgery in a fundamentally new way,' Professor Long said. ' asserted
Long → show → way
Just as email transformed how we communicate, individualised neoantigen therapy has the potential to transform how we treat cancer. asserted
we → transform → cancer
The vaccine, known as intismeran, is being jointly developed by pharmaceutical companies Moderna and MSD. asserted
vaccine → know → companies
Intismeran is an individualised messenger RNA (mRNA) cancer vaccine designed specifically for each patient, based on the unique genetic characteristics of their tumour. asserted
Intismeran → design → tumour
Professor Georgina Long (pictured) led the clinical trial of a world-first cancer vaccine that dramatically reduced the risk of melanoma recurrence or death The trial was conducted across 157 sites worldwide and involved 1,137 patients whose melanoma had been surgically removed but who remained at high risk of the cancer returning. asserted
cancer → picture → risk
None of the participants had previously received drug treatment for their cancer. asserted
None → receive → cancer
The trial ran across a host of Australian sites, including Melanoma Institute Australia, Westmead Hospital in NSW, Princess Alexandra Hospital in Queensland, and the Paula Fox Melanoma and Cancer Centre and Peter MacCallum Cancer Centre in Victoria. asserted
trial → run → Victoria
💬Give feedback
🕘History 🎫Support